FDA/IoM “Uncertainty” Conference Adds Uncertainty to Biogen Growth Plans For Tysabri
This article was originally published in RPM Report
An FDA/Institute of Medicine workshop on characterizing and communicating the uncertainty inherent in risk/benefit decisions touched on an important topic for every sponsor. But two “case studies” included points a very particular interest to Biogen Idec, and to sponsors in the COPD class.
You may also be interested in...
A “safety focused” advisory committee is never something a sponsor looks forward to. But in the case of FDA’s review of GSK’s new Breo Ellipta asthma inhaler, the outcome was generally positive. In this case, FDA seems more concerned that too much emphasis on safety is steering development aware from an area of significant medical need.
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
Physicians and patients need a better understanding of the quality of clinical trial design and data used to approve drugs, say researchers in a study published in JAMA. That led them to suggest a grading system to add another layer of information to FDA approvals, adding another academic suggestion for elaborating, explaining and embellishing FDA action.